The role of biologic agents in damage progression in rheumatoid arthritis: Indirect comparison of data coming from randomized clinical trials

Ennio Giulio Favalli, Francesca Pregnolato, Martina Biggioggero, Pier Luigi Meroni

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: All biologic agents approved for the treatment of rheumatoid arthritis (RA) have been tested versus methotrexate (MTX) for efficacy on damage progression in several randomized clinical trials (RCTs), but direct head-to-head comparisons have never been conducted. The purpose of this investigation is to analyse data coming from main RA RCTs and to perform an indirect comparison. Methods: A systematic review of literature from 1988 to 2011 was conducted. Only randomized, double-blind, controlled, comparative trials, with evaluation of radiographic progression were included. The radiographic score was standardized and mean difference in the percentage of the annual radiographic progression rate was used as the effect measure. Heterogeneity between studies was estimated by I2 test. For each trial, the effect was plotted according to its standard error in a funnel plot. Results: Of 44 potentially relevant trials, 12 RCTs were included in the study. In order to optimize RCTs comparison, studies were stratified in early and late RA group. Main population characteristics were similar in both early and late RA groups, whereas the standardized baseline radiographic score value significantly differs among trials in both early (range 2.7-21.9) and late (range 23.46-75) RA groups. The standardized annual estimated progression is similar across the late RA group. Strong evidence of heterogeneity (I2 = 97%, p = 0.00001) but no asymmetry of the funnel plot was observed in the early RA group. Total mean difference was -16.28 (95% confidence interval [CI] -24.42 to -8.14). For the late RA group a random model was used (I2 = 99%, p = 0.00001) and a total mean difference of -39.25 (95% CI -53.77 to -24.73) was found. Conclusions: All biologic agents provide a favourable effect on disease progression both in early and late RA. The significant heterogeneity among various RCTs did not allow an effective comparison of the performance of biologic agents in each study.

Original languageEnglish
Pages (from-to)213-223
Number of pages11
JournalTherapeutic Advances in Musculoskeletal Disease
Volume4
Issue number4
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Biological Factors
Rheumatoid Arthritis
Randomized Controlled Trials
Confidence Intervals
Population Characteristics
Methotrexate
Disease Progression

Keywords

  • biologic therapy
  • metaanalysis
  • radiographic progression
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

@article{f8a50887192c43359ba3b99d3d15c24e,
title = "The role of biologic agents in damage progression in rheumatoid arthritis: Indirect comparison of data coming from randomized clinical trials",
abstract = "Objectives: All biologic agents approved for the treatment of rheumatoid arthritis (RA) have been tested versus methotrexate (MTX) for efficacy on damage progression in several randomized clinical trials (RCTs), but direct head-to-head comparisons have never been conducted. The purpose of this investigation is to analyse data coming from main RA RCTs and to perform an indirect comparison. Methods: A systematic review of literature from 1988 to 2011 was conducted. Only randomized, double-blind, controlled, comparative trials, with evaluation of radiographic progression were included. The radiographic score was standardized and mean difference in the percentage of the annual radiographic progression rate was used as the effect measure. Heterogeneity between studies was estimated by I2 test. For each trial, the effect was plotted according to its standard error in a funnel plot. Results: Of 44 potentially relevant trials, 12 RCTs were included in the study. In order to optimize RCTs comparison, studies were stratified in early and late RA group. Main population characteristics were similar in both early and late RA groups, whereas the standardized baseline radiographic score value significantly differs among trials in both early (range 2.7-21.9) and late (range 23.46-75) RA groups. The standardized annual estimated progression is similar across the late RA group. Strong evidence of heterogeneity (I2 = 97{\%}, p = 0.00001) but no asymmetry of the funnel plot was observed in the early RA group. Total mean difference was -16.28 (95{\%} confidence interval [CI] -24.42 to -8.14). For the late RA group a random model was used (I2 = 99{\%}, p = 0.00001) and a total mean difference of -39.25 (95{\%} CI -53.77 to -24.73) was found. Conclusions: All biologic agents provide a favourable effect on disease progression both in early and late RA. The significant heterogeneity among various RCTs did not allow an effective comparison of the performance of biologic agents in each study.",
keywords = "biologic therapy, metaanalysis, radiographic progression, Rheumatoid arthritis",
author = "Favalli, {Ennio Giulio} and Francesca Pregnolato and Martina Biggioggero and Meroni, {Pier Luigi}",
year = "2012",
month = "8",
doi = "10.1177/1759720X12449082",
language = "English",
volume = "4",
pages = "213--223",
journal = "Therapeutic Advances in Musculoskeletal Disease",
issn = "1759-720X",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - The role of biologic agents in damage progression in rheumatoid arthritis

T2 - Indirect comparison of data coming from randomized clinical trials

AU - Favalli, Ennio Giulio

AU - Pregnolato, Francesca

AU - Biggioggero, Martina

AU - Meroni, Pier Luigi

PY - 2012/8

Y1 - 2012/8

N2 - Objectives: All biologic agents approved for the treatment of rheumatoid arthritis (RA) have been tested versus methotrexate (MTX) for efficacy on damage progression in several randomized clinical trials (RCTs), but direct head-to-head comparisons have never been conducted. The purpose of this investigation is to analyse data coming from main RA RCTs and to perform an indirect comparison. Methods: A systematic review of literature from 1988 to 2011 was conducted. Only randomized, double-blind, controlled, comparative trials, with evaluation of radiographic progression were included. The radiographic score was standardized and mean difference in the percentage of the annual radiographic progression rate was used as the effect measure. Heterogeneity between studies was estimated by I2 test. For each trial, the effect was plotted according to its standard error in a funnel plot. Results: Of 44 potentially relevant trials, 12 RCTs were included in the study. In order to optimize RCTs comparison, studies were stratified in early and late RA group. Main population characteristics were similar in both early and late RA groups, whereas the standardized baseline radiographic score value significantly differs among trials in both early (range 2.7-21.9) and late (range 23.46-75) RA groups. The standardized annual estimated progression is similar across the late RA group. Strong evidence of heterogeneity (I2 = 97%, p = 0.00001) but no asymmetry of the funnel plot was observed in the early RA group. Total mean difference was -16.28 (95% confidence interval [CI] -24.42 to -8.14). For the late RA group a random model was used (I2 = 99%, p = 0.00001) and a total mean difference of -39.25 (95% CI -53.77 to -24.73) was found. Conclusions: All biologic agents provide a favourable effect on disease progression both in early and late RA. The significant heterogeneity among various RCTs did not allow an effective comparison of the performance of biologic agents in each study.

AB - Objectives: All biologic agents approved for the treatment of rheumatoid arthritis (RA) have been tested versus methotrexate (MTX) for efficacy on damage progression in several randomized clinical trials (RCTs), but direct head-to-head comparisons have never been conducted. The purpose of this investigation is to analyse data coming from main RA RCTs and to perform an indirect comparison. Methods: A systematic review of literature from 1988 to 2011 was conducted. Only randomized, double-blind, controlled, comparative trials, with evaluation of radiographic progression were included. The radiographic score was standardized and mean difference in the percentage of the annual radiographic progression rate was used as the effect measure. Heterogeneity between studies was estimated by I2 test. For each trial, the effect was plotted according to its standard error in a funnel plot. Results: Of 44 potentially relevant trials, 12 RCTs were included in the study. In order to optimize RCTs comparison, studies were stratified in early and late RA group. Main population characteristics were similar in both early and late RA groups, whereas the standardized baseline radiographic score value significantly differs among trials in both early (range 2.7-21.9) and late (range 23.46-75) RA groups. The standardized annual estimated progression is similar across the late RA group. Strong evidence of heterogeneity (I2 = 97%, p = 0.00001) but no asymmetry of the funnel plot was observed in the early RA group. Total mean difference was -16.28 (95% confidence interval [CI] -24.42 to -8.14). For the late RA group a random model was used (I2 = 99%, p = 0.00001) and a total mean difference of -39.25 (95% CI -53.77 to -24.73) was found. Conclusions: All biologic agents provide a favourable effect on disease progression both in early and late RA. The significant heterogeneity among various RCTs did not allow an effective comparison of the performance of biologic agents in each study.

KW - biologic therapy

KW - metaanalysis

KW - radiographic progression

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84868667029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868667029&partnerID=8YFLogxK

U2 - 10.1177/1759720X12449082

DO - 10.1177/1759720X12449082

M3 - Article

C2 - 22859920

AN - SCOPUS:84868667029

VL - 4

SP - 213

EP - 223

JO - Therapeutic Advances in Musculoskeletal Disease

JF - Therapeutic Advances in Musculoskeletal Disease

SN - 1759-720X

IS - 4

ER -